KU ASH 2018 Review: Current Updates in Hematologic Diseases
Avatar

ASH December 2018 - Lymphoma - Axi-cel as Standard of Care and Related Trials

By KU ASH 2018 Review: Current Updates in Hematologic Diseases FEATURING Frederick L. Locke
By KU ASH 2018 Review: Current Updates in Hematologic Diseases FEATURING Frederick L. Locke
0 views
March 19, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Playlist Lymphoma and Myeloma - Cellular Therapy, Efficacy and Safety from Top Trials, Axi-cel, BCMA CAR T Therapy

06:55
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - Lymphoma- Historical Perspective of CAR-T Cell T…

Feat. F. Locke
24:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018- Lymphoma - Efficacy and Safety from ZUMA 1, JULIE…

Feat. F. Locke
14:52
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - Lymphoma - Axi-cel as Standard of Care and Relat…

Feat. F. Locke
03:50
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - Myeloma - BCMA CAR T Therapy for Refractory Pati…

Feat. F. Locke
Thumbs Up
  • March 19, 2019

Recommended

AUTOPLAY
13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

09:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…

Feat. J. Westin
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

Feat. R. Gale
08:23
Total Health

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Feat. J. Chandler, B. Randolph, M. Onciu
08:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outpatient Management of CAR-T and Bi-Speci…

Feat. R. Bansal
15:26
Moffitt Cancer Center

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Feat. A. Lazaryan
04:08
GRACE

CAR T-Cell Therapy Side Effects for Blood Cancers

Feat. A. Goodman
62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
16:03
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New Algorithm for 2L LBCL

Feat. J. Westin
32:52
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

The Improbable History of CAR T-Cells

Feat. C. June
09:45
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Therapeutic Options for Pts With Primary …

Feat. M. Kamdar
20:18
Stanford Medicine

Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell The…

Feat. M. Hamilton
25:06
Scripps Health

Update in the Treatment of R/R DLBCL

Feat. C. Andreadis
30:07
Dipenkumar Modi

Current Management of DLBCL From Frontline to Relapsed Disease

37:44
University of Colorado Division of Hematology

Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas

Feat. M. Kamdar
28:10
Indy Hematology Review

2024 Updates on Understanding & Managing Immune Effector Cell To…

Feat. D. Reeves
10:27
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Rates of CRS and ICANS From CIBMTR Data o…

Feat. J. DiPersio